TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an update.
Hemogenyx Pharmaceuticals announced the successful treatment of a third patient in its Phase I clinical trial of HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia (AML) in adults. The treatment met initial safety criteria and showed early signs of efficacy, with AML cells undetectable in the patient. The trial, which is a dose-escalation study, aims to evaluate safety and several secondary endpoints, including efficacy and survival rates. The results are promising for addressing a critical unmet medical need and could enhance the company’s market position in treating aggressive leukemia forms.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 110,128
Technical Sentiment Signal: Buy
Current Market Cap: £71.57M
See more data about HEMO stock on TipRanks’ Stock Analysis page.